Rohde C, et al. - Researchers examined if antipsychotic medication exposure is linked with increased pneumonia risk and if patients receiving clozapine are at higher risk of developing pneumonia than patients receiving other antipsychotic medications, using a self‐controlled design. Nationwide health registers yielded data from 8,355 antipsychotic‐naïve patients with schizophrenia who initiated a first‐generation antipsychotic medication; development of pneumonia was reported in 0.95% of the patients before exposure, compared with 0.68% after exposure. They identified similar findings in 8,001 antipsychotic‐naïve patients with schizophrenia who received second‐generation antipsychotic medications, with pneumonia development in 0.56% before exposure compared with 0.55% after exposure. Observations revealed no increase in the risk of pneumonia in correlation with most antipsychotic medications. There may be an association of clozapine with elevated risk of developing pneumonia.